The present study investigates the physicochemical properties and stability of a novel lipid-based formulation-surfactant-enriched oil marbles containing abiraterone acetate. While the biopharmaceutical performance of this formulation has been reported recently, this study aims to fill the gap between a promising in vivo performance and industrial applicability. A series of techniques were employed to assess the solid-state characteristics of oil marble cores along with their physicochemical properties upon stability testing. The chemical stability of abiraterone acetate in the formulation was also investigated. The core of the formulation was found to be stable both physically and chemically over 12 months of storage. The in vitro performance of stressed samples was evaluated using a dissolution experiment. The formulation has successfully self-emulsified upon incubation in bio-relevant media, resulting in a fast and complete API release. An important issue connected with the excipient used as a covering material of oil marbles has been identified. The seemingly insignificant water sorption caused agglomeration of the oil marbles and consequently compromised the dissolution rate in some of the stressed samples. Replacing HPMC with lactose as a covering material resulted in more favorable properties upon storage. Overall, it has been shown that oil marbles are an industrially applicable concept of the solidified lipid-based formulation.

Department of Analytical Chemistry Faculty of Science Charles University Prague Czech Republic

Department of Analytical Chemistry University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

Department of Chemical Engineering University of Chemistry and Technology Prague Technická 5 166 28 Prague Czech Republic

DottBonapace and C srl Via A Merli 10 A Cusano Milanino Italy

Zentiva k s U Kabelovny 130 102 37 Prague Czech Republic

Zobrazit více v PubMed

Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P, Brandl M, Bernkop-Schnürch A, Shrestha N, Préat V, Müllertz A, Bauer-Brandl A, Jannin V. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137: 104967. DOI

Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–72. DOI

Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm. 2013;453(1):215–24. DOI

Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharmaceutics. 2013;2013: 848043. DOI

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJH. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315. DOI

Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergström CAS, Porter CJH. 50years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167–94. DOI

Strickley RG, Currently marketed oral lipid-based dosage forms: drug products and excipients, 1st edition ed., Taylor & Francis Group (2007).

Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017;43(11):1743–58. DOI

Carrière F. Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs. Biochimie. 2016;125:297–305. DOI

Bernkop-Schnürch A, Jalil A. Do drug release studies from SEDDS make any sense? J Control Release. 2018;271:55–9. DOI

Siqueira Jørgensen SD, Al Sawaf M, Graeser K, Mu H, Müllertz A, Rades T, The ability of two in vitro lipolysis models reflecting the human and rat gastro-intestinal conditions to predict the in vivo performance of SNEDDS dosing regimens, European Journal of Pharmaceutics and Biopharmaceutics 124 (2018) 116–124.

Joyce P, Dening TJ, Meola TR, Schultz HB, Holm R, Thomas N, Prestidge CA. Solidification to improve the biopharmaceutical performance of SEDDS: opportunities and challenges. Adv Drug Deliv Rev. 2019;142:102–17. DOI

Dokania S, Joshi AK. Self-microemulsifying drug delivery system (SMEDDS)–challenges and road ahead. Drug Deliv. 2015;22(6):675–90. DOI

Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):734–46. DOI

Shah AV, Serajuddin ATM. Development of solid self-emulsifying drug delivery system (SEDDS) I: use of Poloxamer 188 as both solidifying and emulsifying agent for lipids. Pharm Res. 2012;29(10):2817–32. DOI

Becker K, Salar-Behzadi S, Zimmer A. Solvent-free melting techniques for the preparation of lipid-based solid oral formulations. Pharm Res. 2015;32(5):1519–45. DOI

Shukla D, Chakraborty S, Singh S, Mishra B. Lipid-based oral multiparticulate formulations – advantages, technological advances and industrial applications. Expert Opin Drug Deliv. 2011;8(2):207–24. DOI

Boleslavská T, Rychecký O, Krov M, Žvátora P, Dammer O, Beránek J, Kozlík P, Křížek T, Hořínková J, Ryšánek P, Roušarová J, Canová NK, Šíma M, Slanař O, Štěpánek F. Bioavailability enhancement and food effect elimination of abiraterone acetate by encapsulation in surfactant-enriched oil marbles. AAPS J. 2020;22(6):122. DOI

Bormashenko E. Liquid marbles: properties and applications. Curr Opin Colloid Interface Sci. 2011;16(4):266–71. DOI

Ooi CH, Nguyen N-T. Manipulation of liquid marbles. Microfluid Nanofluid. 2015;19(3):483–95. DOI

European Medicines Agency, Zytiga European Public Assessment Report no. EMA/CHMP/542871, 2011.

Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol. 2012;69(6):1583–90. DOI

Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review, NDA 202–379 Review – abiraterone acetate, 2011.

Boleslavská T, Světlík S, Žvátora P, Bosák J, Dammer O, Beránek J, Kozlík P, Křížek T, Kutinová Canová N, Šíma M, Slanař O, Štěpánek F, Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation, European Journal of Pharmaceutics and Biopharmaceutics 151 (2020) 81–90.

Schultz HB, Meola TR, Thomas N, Prestidge CA. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Int J Pharm. 2020;577: 119069. DOI

Goldwater R, Hussaini A, Bosch B, Nemeth P, Comparison of a novel formulation of abiraterone acetate vs. the originator formulation in healthy male subjects: two randomized, open-label, crossover studies, Clinical Pharmacokinetics 56(7) (2017) 803–813.

Food and Drug Administration, Drug Approval Package: YONSA (abiraterone acetate), appl. no. 210308, 2018.

Stella VJ. Chemical drug stability in lipids, modified lipids, and polyethylene oxide-containing formulations. Pharm Res. 2013;30(12):3018–28. DOI

Shrestha H, Bala R, Arora S. Lipid-based drug delivery systems. J Pharm (Cairo). 2014;2014: 801820.

Douša M, Gibala P, Pekárek T. New approach of validation using internal normalization technique for quantification of related substances in raw material, intermediates and pharmaceutical substances by HPLC. J Pharm Biomed Anal. 2015;114:133–8. DOI

International Conference on Harmonisation: Stability Testing of New Drug Substances and Products, ICH Q1A(R2), ICH, 2003.

Block ID, Scheffold F. Modulated 3D cross-correlation light scattering: improving turbid sample characterization. Rev Sci Instrum. 2010;81(12): 123107. DOI

Trunov D, Wilson JF, Ježková M, Šrom O, Beranek J, Dammer O, Šoóš M, Monitoring of particle sizes distribution during Valsartan precipitation in the presence of nonionic surfactant, Int J Pharm 600 (2021) 120515.

Koppel DE, Analysis of macromolecular polydispersity in intensity correlation spectroscopy: the method of cumulants, J Chem Phys (57) (1972) 4814.

Roger V, Cottet H, Cipelletti L. A new robust estimator of polydispersity from dynamic light scattering data. Anal Chem. 2016;88(5):2630–6. DOI

European Medicines Agency. European Pharmacopoeia 10.0. 2019.

Cespi M, Bonacucina G, Misici-Falzi M, Golzi R, Boltri L, Palmieri GF. Stress relaxation test for the characterization of the viscoelasticity of pellets. Eur J Pharm Biopharm. 2007;67(2):476–84. DOI

Zhou D, Qiu Y, Understanding material properties in pharmaceutical product development and manufacturing: powder flow and mechanical properties, 2010.

International Conference on Harmonisation: Validation of analytical procedures: text and Methodology ICH Q2(R1), ICH, 2005.

International Conference on Harmonisation: Impurities in New Drug Products, ICH Q3B(R2). 2006.

Krstić M, Medarević Đ, Đuriš J, Ibrić S, Chapter 12 - Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs, in: A.M. Grumezescu (Ed.), Lipid Nanocarriers for Drug Targeting, William Andrew Publishing2018, pp. 473–508.

Stegemann S. Hard gelatin capsules today - and tomorrow. Bornem: Capsugel; 2002.

Hoag SW, Chapter 27 - Capsules dosage form: formulation and manufacturing considerations, in: Y. Qiu, Y. Chen, G.G.Z. Zhang, L. Yu, R.V. Mantri (Eds.), Developing Solid Oral Dosage Forms (Second Edition), Academic Press, Boston, 2017, pp. 723-747.